by rss feed | Aug 9, 2026 | China gene therapy death, News Feeds, weekly reads
Perinatal tissue and cells have many potential applications. While I’ve mainly focused on placental, umbilical, and amniotic cell products in this area, some potential uses don’t require living cells. As with just about everything, you need good data to...
by rss feed | Aug 2, 2026 | Dynamic Stem Cell Therapy, News Feeds, weekly reads
How well do FDA warning and untitled letters address what the agency sees as noncompliant activities by unproven stem cell clinics and supplier firms? One might think these letters work well given the implicit threat that not complying with them could lead to more...
by rss feed | Jul 26, 2026 | MYC oncogene, News Feeds, Rosalie Sears, weekly reads
Why am I interested in MYC phosphorylation? What is MYC? Long-time readers of The Niche probably remember that the MYC family is one of my primary interests. These proteins are essential for normal development (and stem cell function) as well as contributing to the...
by rss feed | Jul 19, 2026 | News Feeds, thymus anti-aging, weekly reads
When immunology researchers talk about “T cell stem cells” (or stem T cells or T memory stem cells), are they talking more generally about hematopoietic stem cells? No, because those have much broader potential. The most primitive stem cell for T cells can...
by rss feed | Jul 12, 2026 | Colossal Biosciences Trump, News Feeds, weekly reads
Readers of The Niche will recall that I’ve been skeptical of the efforts of the de-extinction firm Colossal Bio. For instance, I don’t believe they de-extincted dire wolves. They did make woolly mice, maybe their fluffiest (in a real sense) achievement....
by rss feed | Jun 28, 2026 | elephant stem cells, FDA, News Feeds, weekly reads
The last eighteen months have been an unprecedented time of unpredictability for the FDA, but moving forward we’re likely going to see an emerging consistency: a higher amount of FDA flexibility on rare diseases. It’s already begun and is likely to...
